Literature DB >> 16420464

Activation of alpha7 acetylcholine receptors augments stimulation-induced hippocampal theta oscillation.

C J Siok1, J A Rogers, B Kocsis, M Hajós.   

Abstract

In the septohippocampal formation alpha7 nicotinic receptors (alpha7 nAChRs) are predominantly expressed by neurons well positioned to modulate hippocampal theta oscillation, such as GABAergic interneurons in the hippocampus, and by both GABAergic and cholinergic septal neurons. In the present experiments, we evaluated the efficacy of the recently developed selective alpha7 nAChR agonist PNU-282987 on hippocampal theta oscillation in anaesthetized rats. This compound shows high affinity for the rat alpha7 nAChRs (Ki = 26 nM) but a negligible activity at other nAChRs. Systemic administration of PNU-282987 significantly enhanced the power (by 40%) of hippocampal theta oscillation induced by electrical stimulation of the brainstem reticular formation. In contrast, the amnesic and muscarinic receptor antagonist scopolamine significantly decreased the power (by 68%) of the stimulation-induced theta oscillation. Given the connection between hippocampal theta oscillation and cognitive processes, it is proposed that precognitive actions of alpha7 nAChR agonists could be mediated, at least in part, by modulation of hippocampal oscillatory activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16420464     DOI: 10.1111/j.1460-9568.2005.04560.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  18 in total

1.  Hippocampal α7 nicotinic ACh receptors contribute to modulation of depression-like behaviour in C57BL/6J mice.

Authors:  Yann S Mineur; Tenna N Mose; Sam Blakeman; Marina R Picciotto
Journal:  Br J Pharmacol       Date:  2017-04-08       Impact factor: 8.739

2.  Cholinergic control in developing prefrontal-hippocampal networks.

Authors:  P Christoph Janiesch; Hanna-Sophie Krüger; Beatrice Pöschel; Ileana L Hanganu-Opatz
Journal:  J Neurosci       Date:  2011-12-07       Impact factor: 6.167

Review 3.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

4.  Theta synchronization between the hippocampus and the nucleus incertus in urethane-anesthetized rats.

Authors:  Ana Cervera-Ferri; Juan Guerrero-Martínez; Manuel Bataller-Mompeán; Alida Taberner-Cortes; Joana Martínez-Ricós; Amparo Ruiz-Torner; Vicent Teruel-Martí
Journal:  Exp Brain Res       Date:  2011-04-09       Impact factor: 1.972

Review 5.  The role of acetylcholine in learning and memory.

Authors:  Michael E Hasselmo
Journal:  Curr Opin Neurobiol       Date:  2006-09-29       Impact factor: 6.627

6.  An opportunistic theory of cellular and systems consolidation.

Authors:  Sara C Mednick; Denise J Cai; Tristan Shuman; Stephan Anagnostaras; John T Wixted
Journal:  Trends Neurosci       Date:  2011-08-20       Impact factor: 13.837

Review 7.  Nicotinic modulation of intrinsic brain networks in schizophrenia.

Authors:  Jason Smucny; Jason Tregellas
Journal:  Biochem Pharmacol       Date:  2013-06-21       Impact factor: 5.858

8.  Trace eyeblink conditioning is impaired in α7 but not in β2 nicotinic acetylcholine receptor knockout mice.

Authors:  Kevin L Brown; David M Comalli; Mariella De Biasi; Diana S Woodruff-Pak
Journal:  Front Behav Neurosci       Date:  2010-10-08       Impact factor: 3.558

9.  Activation of 5-HT6 receptors modulates sleep-wake activity and hippocampal theta oscillation.

Authors:  Susanna Ly; Bano Pishdari; Ling Ling Lok; Mihaly Hajos; Bernat Kocsis
Journal:  ACS Chem Neurosci       Date:  2012-12-10       Impact factor: 4.418

Review 10.  Neurophysiological biomarkers for drug development in schizophrenia.

Authors:  Daniel C Javitt; Kevin M Spencer; Gunvant K Thaker; Georg Winterer; Mihály Hajós
Journal:  Nat Rev Drug Discov       Date:  2008-01       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.